近日，同济大学生命科学与技术学院/东方医院何志颖教授团队在《Journal of Advanced Research》上发表题为“ CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis ...

Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...

Hepatocellular carcinoma or HCC is the most commonly observed form of liver cancer and the fourth leading cause of ...

Egypt: Curative liver resection (LR) can be safely carried out in carefully selected elderly patients with hepatocellular ...

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...

In this cohort study involving noncirrhotic patients with chronic hepatitis B, a new prognostic model based on viral load was ...

Patients with HCC treated with a combination of the immune checkpoint inhibitor atezolizumab and angiogenesis inhibitor ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

华中科技大学同济医院肝脏外科通过其微信公众号发布的说明称，8月29日，肝脏外科自pubpeer网站上得知，学术打假人René Aquarius发现同济医院肝脏外科团队2022年8月28日发表于Biomarker ...

A recent study found that patients with chronic liver disease integrated regular healthcare visits into their daily routines ...

2024年9月13日-17日，欧洲肿瘤内科学会（ESMO）年会将于在西班牙巴塞罗那召开，作为肿瘤内科最高规模的国际盛会，涉及肺癌、乳腺癌、消化道肿瘤、泌尿生殖系统肿瘤等领域的多项研究届时皆将披露最新进展。

Foscenvivint is under clinical development by Eisai and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase ...